| Keryx Rises as Phase III Zerenex Study Readies to Leave the Gate - BioWorld Online |
|
|
BioWorld OnlineBentsur insisted that the drug has shown clear factors that differentiate it from currently marketed medicines to treat hyperphosphatemia in ESRD patients ...Keryx Biopharmaceuticals Initiates Phase 3 Registration Program Of Zerenex ... read more |